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Primary biliary cirrhosis (PBC) is characterized by the autoimmune injury of small intrahepatic bile duct. On this basis, it has
been suggested that the targeted biliary epithelial cells (BEC) play an active role in the perpetuation of autoimmunity by attracting
immune cells via chemokine secretion. To address this issue, we challenged BEC using multiple toll-like receptor (TLR) ligands as
well as autologous liver infiltrating mononuclear cells (LMNC) with subsequent measurement of BEC phenotype and chemokine
production and LMNC chemotaxis by quantifying specific chemokines, specially CX3CL1 (fractalkine). We submit the hypothesis
that BEC are in fact the innocent victims of the autoimmune injury and that the adaptive immune response is critical in PBC.
1. Introduction
Primary biliary cirrhosis (PBC) is a chronic cholestatic liver
disease recognized at histology as chronic nonsuppurative
destructive cholangitis with an autoimmune pathogenesis
supported by Th1 or Th17 cells producing IFN-γ or IL-17
[1, 2]. Several inflammatory cell populations, including T
and B cells, are found around the aﬀected intrahepatic bile
ducts, and chemokines are believed to play a pivotal role for
the infiltration of inflammatory cells [3].
A better understanding of the role of specific chemokines
in liver injury is ancillary to understanding the molecular
mechanisms regulating the autoimmunity process and is ex-
pected to unravel new strategies to treat PBC.
The observed patterns of chemokine expression in nor-
mal and PBC liver are illustrated in Table 1 [4]. In our‘recent
experiments, we cultured EpCAM-positive cells (i.e., biliary
epithelial cells and BEC) isolated by immunobeads from ex-
planted liver tissue and examined the production of che-
mokines by protein array following the stimulation by in-
flammatory cytokines or Toll-like receptor (TLR) ligands
[5]. Our data illustrated that BEC produce proinflammatory
chemokines such as CXCL1, CXCL5, CXCL6, and CXCL8
without any specific stimulation as shown in Figure 1. On the
other hand, BEC challenged with a TLR3 ligand (poly I : C)
manifest a Th1 shift and the production of CCL3, CCL4,
CCL5, and CXCL10. Such production of Th1 chemokines
was further prompted by the interaction between CD40 on
BEC and CD154 on liver infiltrating lymphocytes. Taken
altogether, the evidence support the observation that BEC
induces a proinflammatory environment in the absence of
innate immunity stimulation and induces Th1-sifted envi-
ronment when such stimulation is present.
2. Fractalkine
Fractalkine is characterized as a type-1 transmembrane mol-
ecule with the chemokine domain tethered by a 241-ami-
no acid glycosylated stalk, a 19-amino acid transmembrane
region, and 37-amino acid intracellular tail [6]. The sur-
face-expressed transmembrane fractalkine induces the firm
adhesion of leukocytes expressing its receptor CX3CR1.
After shedding by the disintegrins and metalloproteinases
(ADAM) 10 and 17, fractalkine also acts as a soluble leuko-
cyte chemoattractant. Transmembrane fractalkine expressed
on both endothelial and epithelial cells induces leukocyte
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Figure 1: Chemokines produced by biliary epithelial cells under basal conditions or after stimulation with TLR3 ligand (poly I : C) for 48
hours. Cell-free culture supernatants were analyzed by a protein array kit to evaluate 174 diﬀerent proteins simultaneously. Unstimulated
cells produced detectable amounts of GRO-α/CXCL1, ENA-78/CXCL5, GCP-2/CXCL6, and IL-8/CXCL8, while poly I : C stimulation led to
enhanced MIP-1α/CCL3, MIP-1β/CCL4, RANTES/CCL5, and IP-10/CXCL10.
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Figure 2: (a) Fractalkine production from endothelial cells from PBC and control (chronic hepatitis B and C) livers exposed to TLR ligands.
Endothelial cells produced fractalkine with LTA, poly I : C, LPS, and flagellin with no significant diﬀerences observed between patients and
control livers. (b) BEC did not produce fractalkine with any additional TLR ligand.
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Table 1: Chemokine expression patterns in the portal tract, sinusoidal endothelium, and bile duct of normal and PBC liver.
Chemokine
Portal vein Sinusoidal EC Bile duct
Normal PBC Normal PBC Normal PBC
CXCL9 ± +(?) ± ND − +
CXCL10 ± +(?) ± ND − +
CXCL11 ± ND + ND ND ND
CXCL12 − − − − + ++
CXCL16 + + + + + ++
CCL25 − − − − − −
CCL28 − + − − − ++
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Figure 3: Autologous liver mononuclear cells adhesion assay using endothelial cells and BEC after stimulation with TLR4 ligand (LPS).
Adherent liver mononuclear cells were stained and counted in ten random high-power microscopy fields. Liver mononuclear cells from
PBC livers adhered in greater numbers than did liver mononuclear cells from controls using either endothelial cells or biliary epithelial
cells, whereas liver mononuclear cells adhered only minimally to liver sinusoidal endothelial cells in all instances. Other TLR ligands did not
accelerate liver mononuclear cells adhesion with neither endothelial cells nor biliary epithelial cells (data not shown).
transmigration [7]. Fractalkine is upregulated by inflamma-
tion cytokines such as TNF-α or IFN-γ, it has been proposed
to contribute to inflammatory diseases by promoting the
transmigration of CX3CR1-expressing cells to inflamed
tissues in Crohn disease [8], rheumatoid arthritis, atheroscle-
rosis [9], systemic lupus erythematosus [10], and most
recently PBC [5]. CX3CR1 is expressed on natural killer cells,
monocytes, macrophages, mucosal dendritic cells, CD8+ T
cells, and a subset of eﬀector-memory CD4+ T cells [11, 12].
Human Th1 cells express high levels of CX3CR1 mRNA,
diﬀerent from polarized Th2 cells [13, 14]. Fractalkine is
expressed in limited amounts in the normal human liver,
particularly near branches of the hepatic artery and in small
bile ducts located at the interface between the portal tract
and the hepatic lobule. In the case of acute or chronic viral
hepatitis, fractalkine is detected in the areas of necrosis and
inflammatory infiltration and also at the interface between
the expanded portal tract and the regenerating nodule.
Regenerating epithelial cells of the ductular reaction are also
positive for fractalkine [15]. In kidney allograft transplanta-
tion, fractalkine is expressed in renal tubular epithelial cells,
and the expression is upregulated by TNF-α, the recognized
key proinflammatory cytokine in acute rejection [16]. The
CD4+ and CD8+ T cells expressing CX3CR1 predominantly
produce IFN-γ and TNF-α, and these T cells infiltrate the
synovium in patients with rheumatoid arthritis [17]. In
inflammatory bowel disease (IBD), intestinal microvascular
endothelial cells produce high amounts of fractalkine, and
IBD mucosa as well as periphery contained significantly
more CX3CR1+ cells than control. Fractalkine is a major
contributor to T- and monocytic-cell adhesion to endothelial
cells [18]. In HCV infection, CX3CR1 is susceptible gene for
hepatic fibrosis [19]. In mice models, it is unclear whether
CX3CR1 positive cells are protective or trigger disease [20–
25].
3. Fractalkine and PBC
Fractalkine is peripherally expressed dominantly in patients
with PBC, and is upregulated in BEC of the PBC liver.
CX3CR1 is expressed on infiltrating lymphocytes in the
portal tracts and on intraepithelial T cells of injured bile
ducts [26]. BEC manifesting senescent features in damaged
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Figure 4: The proposed role of fractalkine is illustrated. TLR3 or TLR4 ligands stimulate vascular endothelial cells to produce fractalkine as
chemokine, then fractalkine attracts CX3CR1 positivemonocytes orNK cells. Subsequently, TLR4 ligand stimulated BEC produce fractalkine
as cell adhesion molecule, then fractalkine recruit CX3CR1 positive cells around PBC target cells. This starts the chronic nonsuppurative
destructive cholangitis and perpetuates the autoimmune pathogenesis of disease. Finally, TLR3 ligand stimulated biliary epithelial cells
produce Th1 chemokines, and these chemokines are considered to contribute this autoimmune mechanism.
small bile ducts also overexpress fractalkine [27]. As previ-
ously introduced, in our recent work, we separated BEC as
EpCAM positive and endothelial cells as CD31 positive by
immunobeads and evaluated the production of fractalkine
as chemokine by ELISA. Figure 2(a) illustrates the elevated
production of fractalkine by endothelial cells challenged with
TLR3 ligand (poly I : C) or TLR4 ligand (LPS). Conversely,
BEC did not produce fractalkine with any other TLR ligand
stimulation (Figure 2(b)), and this was not reversed with
the addition of established inflammatory cytokines such as
TNF-α or IFN-γ. Further, we investigated the production
of fractalkine following the interaction between BEC or
endothelial cells and liver infiltrating lymphocytes. As shown
in Figure 3, mononuclear cells adhered with higher aﬃnity
to BEC compared to endothelial cells in the TLR4 ligand
(LPS) stimulation, and this adherence was increased more
in PBC than in other control diseases [5]. Fractalkine
works to modulate inflammation in the BEC of PBC, thus
suggesting that novel therapies to block fractalkine induced
environment may prove beneficial. Based on our data, we
propose a working model on the role of fractalkine as
chemokine or cell adhesion molecule by vascular endothelial
cells and BEC, summarized in Figure 4. First, fractalkine
as chemokine from vascular endothelial cells stimulated via
TLR3 or TLR4 induce CX3CR1 positive monocytes or NK
cells. Second, fractalkine as cell adhesion molecule from
TLR4-stimulated BEC recruit CX3CR1 positive cells around
target cells. This mechanism may trigger the onset of chronic
nonsuppurative destructive cholangitis and autoimmune
mechanism perpetuating the cholangitis. We further submit
that Th1 chemokines produced by BEC stimulated from
TLR3 are important contributors to the autoimmune mech-
anism.
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